Release Date: July 12, 2024
Expiration Date: July 12, 2025
Activity Overview
This educational activity is an archive of the live virtual presentation held on June 2, 2024.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other health care professionals involved in the diagnosis and treatment of multiple myeloma.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate safety and efficacy data from trials exploring anti-CD38 antibodies and novel combinations for newly diagnosed multiple myeloma (NDMM)
- Assess the role and utility of minimal residual disease assessment in the treatment of NDMM
- Address and mitigate treatment-related adverse events associated with therapeutic approaches to treat NDMM
- Investigate the benefits and obstacles associated with shared decision-making with patients with NDMM
Peter Voorhees, MD
Professor of Medicine
Chief, Plasma Cell Disorders Division
Levine Cancer Institute
Atrium Health
Charlotte, NC
Disclosures: Grant/Research Support (paid to institution): AbbVie, GSK, Janssen, Regeneron; Consultant/Advisory Board: AbbVie, AstraZeneca, Bristol Myers Squibb, GSK, Janssen, Karyopharm, Regeneron, Sanofi.
Noopur Raje, MD
Professor of Medicine
Massachusetts General Hospital Cancer Center
Boston, MA
Disclosures: Grant/Research Support: Bluebird Bio; Consultant/Advisory Board: AbbVie, Amgen, Bristol Myers Squibb, Caribou Biosciences, Immuneel Therapeutics, Janssen, Pfizer, Sanofi, Takeda.
Saad Z. Usmani, MD, MBA, FACP, FASCO
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: AbbVie, Amgen, Array Biopharma, Bristol Myers Squibb, Edo Pharma, Genentech, Gilead, GSK, Janssen, Merck, Moderna, Pharmacyclics, Sanofi, Seagen, SkylineDx, Takeda, TeneoBio; Consultant: AbbVie, Amgen, Bristol Myers Squibb, Edo Pharma, Genentech, Gilead, GSK, Janssen, Karyopharm Therapeutics, Merck, Oncopeptides, Sanofi, Seagen, Secura Bio, SkylineDx, Takeda.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here